A full-spectrum Boswellia serrata extract with enhanced bioavailability, and its co-delivered system with curcumin alleviate pain and stiffness associated with moderate spondylitis: a randomized double-blind, placebo-controlled, 3-arm study

Summary

This randomised, double-blind, placebo-controlled, three-arm trial evaluated a full-spectrum Boswellia serrata extract with enhanced bioavailability, both alone and in combination with curcumin, for the management of pain and stiffness in adults with moderate spondylitis. The study likely provides comparative efficacy data across the two active interventions and placebo, contributing evidence on the clinical utility of phytochemical combinations for musculoskeletal inflammation. The enhanced bioavailability formulation represents a methodological focus distinguishing this trial from earlier Boswellia research.

UK applicability

This trial was likely conducted in India and involves a proprietary botanical formulation; whilst spondylitis is prevalent in the UK population, direct applicability depends on regulatory acceptance of the specific formulations and whether findings replicate in diverse ethnic and dietary contexts. The results may inform UK integrative medicine practice and supplement product development, though regulatory pathways for health claims differ under MHRA and FSA frameworks.

Key measures

Pain scores (e.g. VAS or NRS); stiffness indices; possibly inflammatory markers (e.g. CRP, ESR); safety and tolerability measures

Outcomes reported

The study measured changes in pain and stiffness in participants with moderate spondylitis following supplementation with a bioavailability-enhanced Boswellia serrata extract alone or co-delivered with curcumin, compared to placebo. Outcomes likely included validated pain scoring scales, stiffness assessments, and potentially inflammatory biomarkers over the trial duration.

Topic tags